Abcellera Biologics is trading at $13.21, down 4.14%, with biotech-sector weakness providing context, but no clear company-specific explanation was identified.
- Biotech ETF XBI fell 2.50% during the session, while broader U.S. stocks were higher.
- The latest company news located was an October 1 notice of third-quarter results on November 9. Confidence: Low; the available evidence does not establish a direct cause for the October 6 move.